KMID : 1039620130030010025
|
|
Korean Journal of Family Practice 2013 Volume.3 No. 1 p.25 ~ p.32
|
|
Anti-Osteoporotic Effect, Extra-Skeletal Benefi ts and Risks of Other Agents
|
|
Park Joo-Sung
|
|
Abstract
|
|
|
Selective estrogen receptor modulators have an agonistic and antagonistic effect on estrogen receptors and reduce the risk of vertebral fracture and invasive breast cancer. Estrogen with or without progestin reduces the risk of vertebral, onvertebral and hip fracture, and colorectal cancer. Tibolone is a synthetic steroid with estrogenic properties, and it educes the risk of vertebral and non-vertebral fracture and postmenopausal symptoms. Isoflavone derivative ipriflavone oes not reduce fracture risk. Intranasal calcitonin reduces the risk of vertebral fracture and pain in acute vertebral fracture. The purely anabolic teriparatide is available for extremely severe osteoporotic patients and for those who do not respond to other types of therapy. It reduces the risk of vertebral and non-vertebral fracture, and is effective in the treatment of glucocorticoid induced osteoporosis. Strontium ranelate reduces the risk of vertebral and non-vertebral fracture, and may be effective for the management of osteoarthritis. The fully human monoclonal antibody denosumab neutralizes the receptor activator of nuclear factor kappa B ligand, and reduces the risk of vertebral, non-vertebral and hip fracture. These agents have variable extra-skeletal side effects.
|
|
KEYWORD
|
|
Osteoporosis, Contraindications, Selective Estrogen Receptor Modulators, Estrogens, Tibolone, Calcitonin, Teriparatide, Denosumab, Strontium Ranelate
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|